This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Trials in Progress
    • Trials in Progress
      • ECLIPSE Trial
      • Oral EPI-7386
      • SPLASH Trial
    • Right Side
      • PCCTC
        • DORA
        • IRONMAN
        • PROMISE
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
      • Disparities: Social Determinants of Health
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • ASCO 2023
      • AUA 2023
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology
  4. Prostate Cancer

Conferences

Recent Abstracts
ASCO 2023: Treatment and Survival of De Novo mHSPC Among African American US Veterans June 3, 2023
ASCO 2023: PSMA Expression and Response to 177Lu-PSMA-617 in Men with vs. Without DNA Damage Repair Mutations June 3, 2023
ASCO 2023: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer June 3, 2023
ASCO 2023: PSMA PET Findings in an “EMBARK-like” Cohort of Patients with High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer: A Single Center Post-Hoc Retrospective Analysis June 3, 2023
ASCO 2023: The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mHSPC June 3, 2023
ASCO 2023: Adjuvant Everolimus in Patients with Localized Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis from the EVEREST Trial June 3, 2023
ASCO 2023: Nivolumab plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial June 3, 2023
ASCO 2023: Core Biopsy Accuracy and Safety of Biopsy and Preoperative Immunotherapy in Predicting Histological Subtype and Nuclear Grade in ECOG-ACRIN EA8143 Perioperative Nivolumab Versus Observation in Patients with Kidney Cancer Undergoing Nephrectomy June 3, 2023
ASCO 2023: Characterizing Progression to Subsequent Lines of Therapy in Metastatic Renal Cell Carcinoma After Nivolumab plus Ipilimumab (Nivo+Ipi): Results from the IMDC June 3, 2023
ASCO 2023: ARASEC: Open-Label Study of Darolutamide Plus ADT vs ADT in mHSPC Using an External Control Arm June 3, 2023
ASCO 2023: Phase 2 Study of Batiraxcept as Monotherapy, in Combination with Cabozantinib, and in Combination with Cabozantinib and Nivolumab in Patients with Advanced Clear Cell Renal Cell Carcinoma June 3, 2023
ASCO 2023: Assessing PSA Levels as Prognostic of Overall Survival in Men with mHSPC June 3, 2023
ASCO 2023: Head-to-Head Effectiveness and Safety of Pembrolizumab plus Axitinib vs. Nivolumab plus Ipilimumab in Metastatic Renal Cell Carcinoma in the United States June 3, 2023
ASCO 2023: CASSIOPE: A Prospective Noninterventional Study of Cabozantinib Treatment Following Prior Vascular Endothelial Growth Factor - Targeted Therapy in Patients with Advanced Renal Cell Carcinoma June 3, 2023
ASCO 2023: Health-Related Quality of Life (HRQoL) of Risk-Based Patient Subgroups with Advanced Renal Cell Cancer (aRCC) Treated with Nivolumab plus Cabozantinib vs Sunitinib in the CheckMate 9ER Trial June 3, 2023
ASCO 2023: DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States June 3, 2023
ASCO 2023: A Phase I/II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Atezolizumab and Bevacizumab in Patients with Renal Cell Carcinoma June 3, 2023
ASCO 2023: Biomarker-Driven Prospective Clinical Trial in Renal Cell Carcinoma: Developing Machine Learning Models to Allocate Patients to Treatment Arms Using RNA Sequencing June 3, 2023
ASCO 2023: Determinants of Resistance to Nivolumab Monotherapy Investigated Through Genomic and Transcriptomic Analysis of Renal Cell Carcinoma Tumors from the HCRN GU16-260 Study June 3, 2023
ASCO 2023: Darolutamide and Time to Pain Progression by Disease Volume In ARASENS June 3, 2023
Page 3 of 518
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free